Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 31, 2010, Pages 13888-13893

  Van Eersel, Janet ^a   Ke, Yazi D ^a   Liu, Xin ^a   Delerue, Fabien ^a   Kril, Jillian J ^a   Götz, Jürgen ^a   Ittner, Lars M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Frontotemporal lobar degeneration; Neurofibrillary tangle; Protein phosphatase 2A; Transgenic; Treatment

Indexed keywords

PHOSPHATASE; PHOSPHOTRANSFERASE; SELENATE; TAU PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; SELENIUM DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MEMORY; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TAUOPATHY; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; MEMORY; MICE; MICE, TRANSGENIC; MUTATION; NERVE DEGENERATION; PHOSPHORYLATION; PHYSICAL CONDITIONING, ANIMAL; PROTEIN PHOSPHATASE 2; SELENIUM COMPOUNDS; TAU PROTEINS;

EID: 77956385203     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009038107     Document Type: Article

References (53)

1. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112.
2. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-672.
3. Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495.
4. Lewis J, et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491.
5. Roberson ED, et al. (2007) Reducing endogenous tau ameliorates amyloid betainduced deficits in an Alzheimer's disease mouse model. Science 316:750-754.
6. Götz J, Ittner LM (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9:532-544.
7. Rayman MP (2000) The importance of selenium to human health. Lancet 356:233-241.
8. Benton D (2002) Selenium intake, mood and other aspects of psychological functioning. Nutr Neurosci 5:363-374.
9. Akbaraly TN, et al. (2007) Plasma selenium over time and cognitive decline in the elderly. Epidemiology 18:52-58.
10. Cardoso BR, et al. (2010) Nutritional status of selenium in Alzheimer's disease patients. Br J Nutr 103:803-806.
11. Ishrat T, et al. (2009) Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res 1281:117-127.
12. Yim SY, et al. (2009) ERK activation induced by selenium treatment significantly downregulates beta/gamma-secretase activity and Tau phosphorylation in the transgenic rat overexpressing human selenoprotein M. Int J Mol Med 24:91-96.
13. Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-793.
14. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Götz J (2003) Beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem 278:40162-40168.
15. Nuttall KL (2006) Evaluating selenium poisoning. Ann Clin Lab Sci 36:409-420.
16. Ittner LM, et al. (2008) Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci USA 105:15997-16002.
17. Ittner LM, Ke YD, Götz J (2009) Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem 284:20909-20916.
18. Götz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276:529-534.
19. Pennanen L, Welzl H, D'Adamo P, Nitsch RM, Götz J (2004) Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol Dis 15:500-509.
20. Goedert M, Spillantini MG, Cairns NJ, Crowther RA (1992) Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8:159-168.
21. Gong CX, et al. (1995) Phosphatase activity toward abnormally phosphorylated tau: Decrease in Alzheimer disease brain. J Neurochem 65:732-738.
22. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM (2001) PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168: 402-412.
23. Sontag E, et al. (1999) Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem 274:25490-25498.
24. Schild A, Ittner LM, Götz J (2006) Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice. Biochem Biophys Res Commun 343: 1171-1178.
25. Deters N, Ittner LM, Götz J (2009) Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochem Biophys Res Commun 379:400-405.
26. Gong CX, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr Med Chem 15:2321-2328.
27. Janssens V, Goris J (2001) Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439.
28. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC (1996) Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 17:1201-1207.
29. Xing Y, et al. (2008) Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell 133:154-163.
30. Wu J, et al. (2000) Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. EMBO J 19:5672-5681.
31. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22: 1942-1950.
32. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356.
33. Selkoe DJ, Schenk D (2003) Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545-584.
34. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93: 11213-11218.
35. Chirita C, Necula M, Kuret J (2004) Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43:2879-2887.
36. Pickhardt M, et al. (2007) Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46: 10016-10023.
37. Taniguchi S, et al. (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280:7614-7623.
38. Crowe A, et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-7745.
39. Zhang B, et al. (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102:227-231.
40. Matsuoka Y, et al. (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 325:146-153.
41. Pérez M, Hernández F, Lim F, Díaz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5:301-308.
42. Le Corre S, et al. (2006) An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA 103:9673-9678.
43. Dickey CA, et al. (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117:648-658.
44. Luo W, et al. (2007) Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 104:9511-9516.
45. Berger Z, et al. (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15:433-442.
46. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115-9129.
47. Chambraud B, et al. (2010) A role for FKBP52 in Tau protein function. Proc Natl Acad Sci USA 107:2658-2663.
48. Fath T, Ke YD, Gunning P, Götz J, Ittner LM (2009) Primary support cultures of hippocampal and substantia nigra neurons. Nat Protoc 4:78-85.
49. Ke YD, Delerue F, Gladbach A, Götz J, Ittner LM (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS ONE 4:e7917.
50. van Eersel J, et al. (2009) Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J Neural Transm 116:1243-1251.
51. Ittner LM, Koller D, Muff R, Fischer JA, Born W (2005) The N-terminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry 44:5749-5754.
52. Ittner LM, et al. (2005) Compound developmental eye disorders following inactivation of TGFbeta signaling in neural-crest stem cells. J Biol 4:11.
53. Sadot E, Heicklen-Klein A, Barg J, Lazarovici P, Ginzburg I (1996) Identification of a tau promoter region mediating tissue-specific-regulated expression in PC12 cells. J Mol Biol 256:805-812.